LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

Announcement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Decade Energy and Infrastructure Investor — to the Company’s Board of Directors

BOCA RATON, FLA, June 03, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (the “Company”), today announced that it has entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $16,566,027 of shares of common stock and pre-funded warrants at an offering price of (i) $6.31 per share of common stock, and (ii) $0.0001 per pre-funded warrant. The entire transaction was priced at the market under Nasdaq rules. The financing materially strengthens the Company’s balance sheet and provides additional flexibility to pursue its strategic priorities.

The offering consisted of the sale of 2,625,362 shares of common stock and pre-funded warrants, each pre-funded warrant entitling the holder to purchase one share of common stock (and the common stock issuable from time to time upon exercise of such pre-funded warrants). The public offering price is $6.31 per share of common stock (or $6.3099 for each pre-funded warrant, which is equal to the public offering price per common share sold in the offering minus an exercise price of $0.0001 per pre-funded warrant). The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full.

Aggregate gross proceeds to the Company are expected to be approximately $16,566,027. The transaction is expected to close on or about June 3, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering, together with its existing cash, for general corporate purposes, working capital, and to support the Company’s strategic initiatives.

“With this financing, LIXTE moves forward with a materially stronger balance sheet and the flexibility to pursue its next phase of growth,” said Geordan Pursglove, Chief Executive Officer of LIXTE Biotechnology Holdings. “We were privileged to recently welcome Stuart Porter, founder of Denham Capital, to our Board. Stu brings more than three decades of investment experience and one of the most respected track records in the energy and infrastructure sectors, and his counsel will be invaluable as we evaluate and execute on our strategic priorities. This capital positions us to move forward with conviction and to create long-term value for shareholders.”

Sichenzia Ross Ference Carmel LLP acted as counsel to the Company.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on May 2, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s strategic priorities, product development and business prospects, and the anticipated use of proceeds, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533

Released June 3, 2026